News Archive

February 2020

• Key Release Feb 28, 2020

  Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

  Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.…
• Key Release Feb 28, 2020

  Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle

  Les actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow…
• 
  Story Feb 25, 2020 People and Culture

  Parental Leave at Novartis: Alfred’s story

  At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.

• Press Release Feb 25, 2020

  Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

  LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
• 
  Story Feb 24, 2020 Discovery

  Shaping the future of sickle cell disease

  Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.

• Press Release Feb 24, 2020

  Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)

  Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
• 
  Story Feb 18, 2020 Access to Healthcare

  Collaboration is strengthening care for chronic illness in Ethiopia

  Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.

• Press Release Feb 17, 2020

  Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide

  Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…
• Press Release Feb 11, 2020

  Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

  FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 …
• Statement Feb 05, 2020

  AVXS-101 Managed Access Program

• Featured News Feb 04, 2020

  World Cancer Day 2020

  Novartis is supporting World Cancer Day by reimagining cancer in the workplace through a dedicated global program.

• 
  Story Feb 04, 2020 People and Culture

  Reimagining cancer in the workplace

  Novartis is strongly committed in helping and supporting employees impacted by cancer through the program Ensemble – Caring for Colleagues (Ensemble).